DR DALEY: Mrs T is a 40-year-old married mother of 3 children with a strong family history of breast cancer who is considering genetic testing and tamoxifen therapy. She lives on Cape Cod, Mass, and works at home caring for her 3 children, ages 7, 5, and 2. Her health insurance is provided through a managed care plan.
Mrs T is in good health. She is of Dutch and English ancestry. Her maternal grandmother was diagnosed with breast cancer in her seventh decade and was treated with surgery. She died of causes unrelated to breast cancer. Mrs T's mother developed breast cancer and died of complications related to breast cancer metastatic to bone. Her sister developed breast cancer at age 26 and died at age 38 of complications related to metastatic breast cancer to lymphatics and lung. Mrs T has had yearly mammography since age 23 and semiannual breast examinations. She practices breast self-examination. Mrs T has decided not to have genetic testing because she is aware that negative test results do not assure her that she will not develop breast cancer. She says that having a prophylactic mastectomy would be a "big" decision. After several months of consideration, she recently began a course of tamoxifen and has not experienced any noticeable adverse effects. She is ambivalent about genetic testing, wants to know what the future of "gene therapy" is, and is curious about what the future holds for her 2-year-old daughter.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 14
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature Sequencing the human genome—identifying the entire sequence of base pairs in the 25 ...
Mutation
All results at JAMAevidence.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.